ARIAD Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals

ARIA 23.99

0.0%

Feb 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rolf Schoch who wrote ()	2/16/2000 10:08:00 PM
From: scott_jiminez	Read Replies (1) of 4474

Ariad has published another article - this time a review in Gene Therapy. Regulated gene expression systems. Clackson T ARIAD Gene Therapeutics Inc, 26 Landsdowne Street, Cambridge, MA 02139, USA. Most gene therapy research to date has focused on solving the delivery problem - getting genes efficiently and stably into target cells and tissues. Those working on systems for regulating the expression of genes once delivered have often been accused of trying to run before they can walk. Yet regulation is likely to be essential if gene therapy is to realize its full potential as a mainstream clinical option for delivering proteins. Dramatic progress has been made in designing and testing systems in which expression is controlled by orally active drugs. The next few years should see the first clinical trials of drug-regulated gene therapies. Gene Therapy (2000) 7, 120-125. The fact that Ariad is now writing reviews about regulation of expression in gene therapy suggests the company is perceived as one of the leaders in the field. And not just in terms of NASDAQ science This is good.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next